Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights

被引：5

作者：

Hofer, Matthias P. ^{[1
]}

Criscuolo, Paola ^{[1
]}

Shah, Nilay ^{[2
]}

ter Wal, Anne L. J. ^{[1
]}

Barlow, James ^{[1
]}

机构：

[1] Imperial Coll Business Sch, London, England

[2] Imperial Coll London, Dept Chem Engn, London, England

来源：

FRONTIERS IN MEDICINE | 2022年 / 9卷

关键词：

medicines regulation; pharmaceutical innovation; United Kingdom; Brexit; health policy; Medicines and Healthcare products Regulatory Agency; DRUGS;

D O I：

10.3389/fmed.2022.1011082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Brexit was presented as an opportunity to promote innovation by breaking free from the European Union regulatory framework. Since the beginning of 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) has operated as the independent regulatory agency for the United Kingdom. The MHRA's regulatory activity in 2021 was analyzed and compared to that of other international regulatory bodies. The MHRA remained reliant on EU regulatory decision-making for novel medicines and there were significant regulatory delays for a small number of novel medicines in the UK, the reasons being so far unclear. In addition, the MHRA introduced innovation initiatives, which show early promise for quicker authorization of innovative medicines for cancer and other areas of unmet need. Longer-term observation and analysis is needed to show the full impact of post-Brexit pharmaceutical regulatory policy.

引用

页数：10

共 50 条

[1] IT Law in the United Kingdom after Brexit
Lloyd, Ian
COMPUTER LAW & SECURITY REVIEW, 2017, 33 (02) : 182 - 192
[2] The macroeconomic stability of United Kingdom after Brexit
Kotlinski, Kamil
EKONOMIA I PRAWO-ECONOMICS AND LAW, 2023, 22 (03): : 599 - 611
[3] An integrated national pharmaceutical policy for the United Kingdom?
Walley, T
Earl-Slater, A
Haycox, A
Bagust, A
BRITISH MEDICAL JOURNAL, 2000, 321 (7275): : 1523 - 1526
[4] CONSEQUENCES OF BREXIT ON THE CRIMINAL POLICY OF THE EUROPEAN UNION AND UNITED KINGDOM
Acale Sanchez, Maria
REVISTA DE DERECHO COMUNITARIO EUROPEO, 2018, (59): : 97 - 142
[5] The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
Milne-Ives, Madison
Lam, Ching
van Velthoven, Michelle
Meinert, Edward
JMIR RESEARCH PROTOCOLS, 2020, 9 (09):
[6] Transition of Pharmaceutical Regulations: The New Regulatory Era after Brexit
Ankit, Trivedi
Shrikalp, Deshpande
Maitreyi, Zaveri
Kumar, Jain Praveen
Kiran, Kolhe
JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (47A) : 804 - 817
[7] Spatial policy in the United Kingdom: Regulatory experimentation in the after-Fordist era
Uitermark J.
Journal of Housing and the Built Environment, 2002, 17 (4) : 385 - 407
[8] Agreeing to Disagree: The European Union and the United Kingdom after Brexit
Bradley, Kieran
EUROPEAN CONSTITUTIONAL LAW REVIEW, 2020, 16 (03) : 379 - 416
[9] CREATING ORDER IN CHAOS - THE IMPACT OF BREXIT ON THE REGULATORY ENVIRONMENT IN EUROPE AND THE UNITED KINGDOM
Wang, G. D.
Macaulay, R.
VALUE IN HEALTH, 2017, 20 (09) : A700 - A701
[10] Brexit and the Uncertain Future of Fisheries Policy in the United Kingdom: Political and Governance Challenges
Huggins, Christopher
Connolly, John
McAngus, Craig
Van der Zwet, Arno
OCEAN YEARBOOK, 2020, 34 (01): : 20 - 42

← 1 2 3 4 5 →